Clinical trials: New Onset Type-1 Diabetes
Type 1 Diabetes Mellitus
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with…
- Trial name
- NCT02093221
- Testing
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI
- Where
- 36 sites in United States
- Volunteers
- 76 people
- Sponsor
- Grifols Therapeutics LLC
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.
Type 1 Diabetes Mellitus
Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus
A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes mellitus.
- Trial name
- NCT00545857
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stony Brook University
Diabetes Mellitus, Type 1
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure.
- Trial name
- NCT03182426
- Testing
- Plerixafor, Alemtuzumab, Anakinra
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
Type 1 Diabetes Mellitus
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of…
- Trial name
- NCT07142252
- Testing
- Rezpegaldesleukin
- Where
- 15 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
- Trial name
- NCT04598893
- Testing
- Teplizumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 188 people
- Sponsor
- Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
The optimal insulin regimen for children and adolescents with newly diagnosed type 1 diabetes remains unknown. The purpose of this study is to determine whether a split evening injection regimen (insulin injections before…
- Trial name
- NCT00146484
- Testing
- Twice Daily versus Three Times Daily Insulin Injections
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Eastern Ontario
Type 1 Diabetes Mellitus
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
The study is a randomized, double-masked, placebo-controlled, Phase 1 dose-escalation clinical trial. The objective of the trial is to determine if IBC adjuvanted with MAS-1 is safe and will favor tolerogenic pathways to restore…
- Trial name
- MER3101 (NCT03624062)
- Testing
- MAS-1 adjuvanted Insulin B-chain
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Colorado, Denver